1. Prognosis of Pulmonary Arterial Hypertension*
Vallerie V. McLaughlin, MD, FCCP, Kenneth W. Presberg, MD, FCCP, Ramona L. Doyle, MD, FCCP, Steven H. Abman, MD, Douglas C. McCrory, MD, MHSc, Terry Fortin, MD, Gregory Ahearn, MD 
CHEST 
Volume 126, Issue 1, Pages 78S-92S (July 2004)
DOI: /chest.126.1_suppl.78S
Copyright © 2004 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Mean survival of patients with PAH based on etiology. CHD = congenital heart disease; CVD = collagen vascular disease; HIV = human immunodeficiency virus related; IPAH = idiopathic pulmonary arterial hypertension; Portopulm = portopulmonary hypertension.
CHEST  , 78S-92SDOI: ( /chest.126.1_suppl.78S)
Copyright © 2004 The American College of Chest Physicians Terms and Conditions

3. Figure 2
Impact made by epoprostenol on survival in patients with IPAH.
CHEST  , 78S-92SDOI: ( /chest.126.1_suppl.78S)
Copyright © 2004 The American College of Chest Physicians Terms and Conditions